Filtered By:
Specialty: Neurology
Infectious Disease: Coronavirus

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 532 results found since Jan 2013.

Pharmacotherapy for SARS-CoV-2 and Seizures for drug repurposing presumed on Mechanistic Targets
CONCLUSION: These findings would hopefully provide the basis for initiating further studies on the pathogenesis and drug targeting strategies for this emerging infection accompanied with seizures or in people with epilepsy.PMID:34645381 | DOI:10.2174/1874467214666211013122528
Source: Epilepsy Curr - October 14, 2021 Category: Neurology Authors: Divya Goel Ankit Srivastava Ángel Aledo-Serrano Anuja Krishnan Divya Vohora Source Type: research

Virtual rounding in stroke care and neurology education during the COVID-19 pandemic - a residency program survey
During the coronavirus disease 2019 (COVID-19) pandemic, we instituted virtual inpatient stroke rounds and acute stroke evaluations via telemedicine in the emergency department. We sought to explore trainees ’ and experienced providers’ views on stroke care and education.
Source: Journal of Stroke and Cerebrovascular Diseases - October 14, 2021 Category: Neurology Authors: Murali K. Kolikonda, Elena Blaginykh, Peter Brown, Shivakrishna Kovi, Lucy Q. Zhang, Ken Uchino Source Type: research

Utilization and Outcomes of Acute Revascularization Treatment in Ischemic Stroke Patients with SARS-CoV-2 Infection
Our understanding of outcomes in acute ischemic stroke patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following acute revascularization treatments (as intravenous thrombolysis and/or thrombectomy) is based on small case series.1-3. An international panel4 cautioned regarding the potential for high rate of death or disability and post thrombolytic intracerebral hemorrhage (ICH)s in acute ischemic stroke patients with SARS-CoV-2 infection due to elevated concentrations of inflammation and hypercoagulability markers such as leukocytosis, and C reactive protein and D dimers and multisystem dysfunction.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2021 Category: Neurology Authors: Adnan I. Qureshi, William I. Baskett, Wei Huang, Muhammad F. Ishfaq, S. Hasan Naqvi, Brandi R. French, Farhan Siddiq, Camilo R. Gomez, Chi-Ren Shyu Tags: SARS-CoV-2 and acute revascularization Source Type: research

Utilization and Outcomes of Acute Revascularization Treatments in Ischemic Stroke Patients with SARS-CoV-2 Infection
Our understanding of outcomes in acute ischemic stroke patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following acute revascularization treatments (as intravenous thrombolysis and/or thrombectomy) is based on small case series.1 –3 An international panel4 cautioned regarding the potential for high rate of death or disability and post thrombolytic intracerebral hemorrhage (ICH)s in acute ischemic stroke patients with SARS-CoV-2 infection due to elevated concentrations of inflammation and hypercoagulability markers such as leukocytosis, and C reactive protein and D dimers and multisystem dysfunction.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2021 Category: Neurology Authors: Adnan I. Qureshi, William I. Baskett, Wei Huang, Muhammad F. Ishfaq, S. Hasan Naqvi, Brandi R. French, Farhan Siddiq, Camilo R. Gomez, Chi-Ren Shyu Source Type: research

Successful Endovascular Therapy in COVID-19 Associated Pediatric Ischemic Stroke
Cerebrovascular diseases attributed to coronavirus disease 2019 (COVID-19) are uncommon but can result in devastating outcomes. Pediatric acute ischemic strokes are themselves rare and with very few large vessel occlusion related acute ischemic strokes attributed to COVID-19 described in the literature as of date. COVID-19 pandemic has contributed to acute stroke care delays across the world and with pediatric endovascular therapy still in its infancy, it poses a great challenge in facilitating good outcomes in children presenting with acute ischemic strokes in the setting of COVID-19.
Source: Journal of Stroke and Cerebrovascular Diseases - October 4, 2021 Category: Neurology Authors: Dinesh V. Jillella, Bryan Philbrook, Elissa Ortolani, Jonathan A. Grossberg, Tristan Stani, Owen Samuels, Cederic Pimentel, Amy Harrison, Ashok R. Polu, Benjamin I. Siegel, Ian McCullough, Michael Cawley, Fadi Nahab Tags: Case Report Source Type: research

Acute Neurologic Manifestations of Respiratory Viruses
This article describes the most common respiratory viruses that have neurologic manifestations, with a focus on SARS-CoV-2 and COVID-19. RECENT FINDINGS In vitro and in vivo studies have better elucidated the neurotropism of various respiratory viruses. Understanding host cell receptors that mediate viral binding and entry not only demonstrates how viruses enter host cells but also provides possible mechanisms for therapeutic interventions. Elucidation of SARS-CoV-2 binding and fusion with host cells expressing the angiotensin-converting enzyme 2 (ACE2) receptor may also provide greater insights into its systemic an...
Source: CONTINUUM: Lifelong Learning in Neurology - October 1, 2021 Category: Neurology Tags: REVIEW ARTICLES Source Type: research

Changes in Stroke Patients ’ Health-Seeking Behavior by COVID-19 Epidemic Regions: Data from the Korean Stroke Registry
Conclusion: Korean stroke patients in a CO ­VID-19 epidemic region exhibited distinct changes in health-seeking behaviors. Appropriate triage system and public education regarding the importance of early treatment are needed during the COVID-19 pandemic.Cerebrovasc Dis
Source: Cerebrovascular Diseases - September 30, 2021 Category: Neurology Source Type: research

Acute Ischaemic Stroke Incidence after Coronavirus Vaccine in Indonesia: Case Series
Curr Neurovasc Res. 2021 Sep 26. doi: 10.2174/1567202618666210927095613. Online ahead of print.ABSTRACTCoronavirus disease-19 (COVID-19) is an infectious disease with high morbidity and mortality rates. Indonesia had reported a 2.8% of mortality rate up to June 2021. A strategy to control the virus spreading is by vaccination. The Indonesian Food and Drug Monitoring Agency had approved the use of CoronaVac, an inactivated virus vaccine developed by Sinovac. Most adverse events following immunization (AEFI) for CoronaVac are mild, and the most common symptoms are injection-site pain, headache, and fatigue. Neurovascular adv...
Source: Current Neurovascular Research - September 28, 2021 Category: Neurology Authors: Rakhmad Hidayat Dinda Diafiri Ramdinal Aviesena Zairinal Ghafur Rasyid Arifin Faiza Azzahroh Nita Widjaya Devi Nurfadila Fani Taufik Mesiano Mohammad Kurniawan None Al Rasyid Astuti Giantini Salim Haris Source Type: research